StreetInsider.com News Articles

Form SCHEDULE 13G RxSight, Inc. Filed by: BlackRock Portfolio Management LLC

Fri, 17 Jul 2026 11:34:00 -0400

si-local-file:///var/storage/secattach/20260717/26783088.html

Form SCHEDULE 13G RxSight, Inc. Filed by: BlackRock Portfolio Management LLC

Fri, 17 Jul 2026 11:34:00 -0400

si-local-file:///var/storage/secattach/20260717/26783088.html

Form 8-K RxSight, Inc. For: Jul 13

Wed, 15 Jul 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260715/26774423.html

Form 8-K RxSight, Inc. For: Jul 13

Wed, 15 Jul 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260715/26774423.html

RxSight names Mottiwala as CEO, Kurtz shifts to chief medical officer

Wed, 15 Jul 2026 16:15:11 -0400

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who moves to the role of Chief Medical Officer.

Mottiwala most recently served as Chief Commercial Officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals. Before those positions, he spent more than a decade at Allergan in senior leadership roles within its eye care and broader commercial organization. He holds a B.S. in Biochemistry from the University of California, San Diego, and an MBA from the University of Southern California.

In connection with

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

Wed, 15 Jul 2026 16:15:00 -0400

ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.

Mr. Mottiwala brings extensive commercial leadership experience across eye care, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as Chief Commercial Officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals. Before that, he spent more than a decade at Allergan,

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

Wed, 15 Jul 2026 16:15:00 -0400

RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities

Tue, 07 Jul 2026 12:24:53 -0400

BofA Securities analyst Craig Bijou lowered the price target on RxSight Inc. (NASDAQ: RXST) to $6.50 (from $8.00) while maintaining a Underperform rating.

The analyst comments "RXST pre-A’d preliminary Q2 sales of $27m vs Street of $32m and lowered 2026 guidance by $13m at midpoint (rev guide now $110-$120m vs prior $120-$135m). RXST pointed to elevated levels of competitive trialing and lower consumer sentiment. RXST also announced a strategic collaboration with ALC to develop and commercialize light adjustable PCIOLs using RXST's LAL technology. The partnership allows RXST to leverage its technology in an area it doesn’t participate in today, but the

RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities

Tue, 07 Jul 2026 12:24:53 -0400

BofA Securities analyst Craig Bijou lowered the price target on RxSight Inc. (NASDAQ: RXST) to $6.50 (from $8.00) while maintaining a Underperform rating.

RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced

Tue, 07 Jul 2026 06:56:13 -0400

Stifel analyst Tom Stephan reiterated a Hold rating and $8.00 price target on RxSight Inc. (NASDAQ: RXST).

The analyst commented, "RXST announced a strategic collaboration with ALC (Hold, $68.33) to develop/commercialize light-adjustable presbyopia-correcting (PC) IOLs, which provides RXST with an immediate cash injection ($60M) as well as meaningful potential milestone payments (up to $140M) and royalties on net sales (30%). Additionally, we were encouraged to see RXST unveil its LAL pipeline, with intermediate-term launches expected (we believe 2-3 years from now) of a next-gen LAL/LAL+ and an LAL Toric—highlighted by new hybrid lens material potentially allowing for fewer post-op treatments. Recall,

RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced

Tue, 07 Jul 2026 06:56:13 -0400

Stifel analyst Tom Stephan reiterated a Hold rating and $8.00 price target on RxSight Inc. (NASDAQ: RXST).

Alcon and RxSight team up to develop light-adjustable cataract lenses

Mon, 06 Jul 2026 16:16:03 -0400

Alcon (NYSE: ALC) and RxSight, Inc. (NASDAQ: RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) for use following cataract surgery, according to a press release issued July 6, 2026.

Under the agreement, the two companies will combine RxSight's post-operative light-adjustable lens technology with Alcon's PCIOL optical designs to create a co-developed product intended to allow surgeons to fine-tune visual outcomes after cataract surgery.

RxSight will receive a $60 million upfront payment to begin development. The company could receive up to an additional $140 million in payments contingent on development and regulatory milestones. Alcon will lead global commercialization,

Alcon and RxSight team up to develop light-adjustable cataract lenses

Mon, 06 Jul 2026 16:16:03 -0400

Alcon and RxSight team up to develop light-adjustable cataract lenses

Mon, 06 Jul 2026 16:16:03 -0400

Alcon and RxSight team up to develop light-adjustable cataract lenses

Mon, 06 Jul 2026 16:16:03 -0400

RxSight cuts 2026 sales outlook, citing competitive headwinds

Mon, 06 Jul 2026 16:15:55 -0400

RxSight, Inc. (NASDAQ: RXST) reported preliminary second-quarter 2026 revenue of approximately $32 million to $34 million, which includes $5 million to $7 million recognized from its strategic collaboration agreement with Alcon, according to a company statement.

Sales for the quarter totaled approximately $27 million, with 24,917 Light Adjustable Lens (LAL) units and 11 Light Delivery Device (LDD) units sold, plus one rental unit placed. The company held approximately $209 million in cash, cash equivalents, and short-term investments as of June 30, 2026.

RxSight revised its full-year 2026 sales guidance to $110 million to $120 million, down from a prior range of $120

RxSight cuts 2026 sales outlook, citing competitive headwinds

Mon, 06 Jul 2026 16:15:55 -0400

RxSight revised its full-year 2026 sales guidance to $110 million to $120 million, down from a prior range of $120

RxSight cuts 2026 sales outlook, citing competitive headwinds

Mon, 06 Jul 2026 16:15:55 -0400

RxSight revised its full-year 2026 sales guidance to $110 million to $120 million, down from a prior range of $120

RxSight cuts 2026 sales outlook, citing competitive headwinds

Mon, 06 Jul 2026 16:15:55 -0400

RxSight revised its full-year 2026 sales guidance to $110 million to $120 million, down from a prior range of $120

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs